Ironwood Pharma (IRWD) Misses Q4 EPS by 4c, Misses on Revenue; Offers FY25 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
February 27, 2025 7:00 AM ESTAnnounced positive data from open-label extension study demonstrating an increased number of patients on apraglutide achieving enteral autonomy over time
Initiated rolling NDA submission; on track to be completed in Q3 2025
LINZESS® (Iinaclotide) EUTRx prescription demand growth of 11% for full-year 2024 year-over-year
2024 Ironwood revenue of $351 million, GAAP net income of $2 million and adjusted EBITDA of $101 million
BOSTON--(BUSINESS... More
